{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:58:20Z","timestamp":1785225500216,"version":"3.55.0"},"reference-count":140,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Despite significant breakthroughs in the understanding of immunological and pathophysiological features for immune-mediated kidney diseases, a proportion of patients exhibit poor responses to current therapies or have been categorized as refractory renal disease. Engineered T cells have emerged as a focal point of interest as a potential treatment strategy for kidney diseases. By genetically modifying T cells and arming them with chimeric antigen receptors (CARs), effectively targeting autoreactive immune cells, such as B cells or antibody-secreting plasma cells, has become feasible. The emergence of CAR T-cell therapy has shown promising potential in directing effector and regulatory T cells (Tregs) to the site of autoimmunity, paving the way for effective migration, proliferation, and execution of suppressive functions. Genetically modified T-cells equipped with artificial receptors have become a novel approach for alleviating autoimmune manifestations and reducing autoinflammatory events in the context of kidney diseases. Here, we review the latest developments in basic, translational, and clinical studies of CAR-based therapies for immune-mediated kidney diseases, highlighting their potential as promising avenues for therapeutic intervention.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1408718","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T04:39:12Z","timestamp":1724128752000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Current progress in CAR-based therapy for kidney disease"],"prefix":"10.3389","volume":"15","author":[{"given":"Dan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00766-1","article-title":"The role of complement in kidney disease","volume":"19","author":"Petr","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.10.018","article-title":"Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Floege","year":"2019","journal-title":"Kidney Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1053\/j.ajkd.2021.07.019","article-title":"Advances in understanding of pathogenesis and treatment of immune-mediated kidney disease: A review","volume":"79","author":"Kant","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1024068","article-title":"Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives","volume":"13","author":"Hartinger","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.3390\/ijms21124303","article-title":"CAR-T Cell Therapy","volume":"21","author":"Ahmad","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30277-5","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis","volume":"7","author":"Anagnostou","year":"2020","journal-title":"Lancet Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological Malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/art.41812","article-title":"Is there a place for chimeric antigen receptor-T cells in the treatment of chronic autoimmune rheumatic diseases","volume":"73","author":"Orvain","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00816-y","article-title":"Glomerulonephritis: immunopathogenesis and immunotherapy","volume":"23","author":"Anders","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.clim.2016.06.011","article-title":"Unraveling the immunopathogenesis of glomerular disease","volume":"169","author":"Dickinson","year":"2016","journal-title":"Clin Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-021-03509-5","article-title":"Immune-mediated glomerular diseases: new basic concepts and clinical implications","volume":"385","author":"Panzer","year":"2021","journal-title":"Cell Tissue Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31720","article-title":"APC-derived cytokines and T cell polarization in autoimmune inflammation","volume":"117","author":"Gutcher","year":"2007","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.112","article-title":"T helper type 17 cells in immune-mediated glomerular disease","volume":"13","author":"Krebs","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09430915","article-title":"Antibodies","volume":"11","author":"Hoffman","year":"2016","journal-title":"More Clin J Am Soc Nephrol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41581-018-0074-7","article-title":"Effector and regulatory B cells in immune-mediated kidney disease","volume":"15","author":"Oleinika","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2016.18","article-title":"Biologics for the treatment of autoimmune renal diseases","volume":"12","author":"Holdsworth","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.08.007","article-title":"Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis","volume":"9","author":"Dorner","year":"2009","journal-title":"Autoimmun Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-021-03485-w","article-title":"Complement catalyzing glomerular diseases","volume":"385","author":"Zipfel","year":"2021","journal-title":"Cell Tissue Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad186","article-title":"The plethora of immunomodulatory drugs: opportunities for immune-mediated kidney diseases","volume":"38","author":"Odler","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.21037\/tp","article-title":"C3dg and MAC complement depositions in the renal histopathology of patients with lupus nephropathy","volume":"12","author":"Shi","year":"2023","journal-title":"Transl Pediatr"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-021-00999-0","article-title":"Relationship of complement activation pathway to clinical and pathological characteristics and renal outcome in patients with lupus nephritis","volume":"81","author":"Su","year":"2022","journal-title":"Z Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J Clin Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00157","article-title":"Alternative pathway dysregulation and the conundrum of complement activation by igG4 immune complexes in membranous nephropathy","volume":"7","author":"Borza","year":"2016","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021101384","article-title":"Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy","volume":"33","author":"Gao","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheumatol.","article-title":"Updates in ANCA-associated vasculitis","volume":"9","author":"Ross","year":"2022","journal-title":"Eur J Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/BOR.0000000000000667","article-title":"Deadliest catch: neutrophil extracellular traps in autoimmunity","volume":"32","author":"Goel","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.03.010","article-title":"Transcription factor Nrf2 activation regulates NETosis, endothelial injury, and kidney disease in myeloperoxidase-positive antineutrophil cytoplasmic antibody-associated vasculitis","volume":"105","author":"Ueda","year":"2024","journal-title":"Kidney Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.08.006","article-title":"Release of extracellular DNA influences renal ischemia reperfusion injury by platelet activation and formation of neutrophil extracellular traps","volume":"91","author":"Jansen","year":"2017","journal-title":"Kidney Int"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/db22-0153","article-title":"Neutrophil extracellular traps induce glomerular endothelial cell dysfunction and pyroptosis in diabetic kidney disease","volume":"71","author":"Zheng","year":"2022","journal-title":"Diabetes"},{"key":"B37","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41419-022-05138-4","article-title":"GSDMD-dependent neutrophil extracellular traps promote macrophage-to-myofibroblast transition and renal fibrosis in obstructive nephropathy","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1253667","article-title":"NETosis: an emerging therapeutic target in renal diseases","volume":"14","author":"Juha","year":"2023","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1621676","DOI":"10.1080\/2162402X.2019.1621676","article-title":"T cells engrafted with a UniCAR 28\/z outperform UniCAR BB\/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression","volume":"8","author":"Kegler","year":"2019","journal-title":"Oncoimmunology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.09.016","article-title":"CAR T cell immunotherapy in hematology and beyond","volume":"186","author":"Rossig","year":"2018","journal-title":"Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/stem.2715","article-title":"Concise review: emerging principles from the clinical application of chimeric antigen receptor T cell therapies for B cell Malignancies","volume":"36","author":"Jain","year":"2018","journal-title":"Stem Cells"},{"key":"B44","doi-asserted-by":"publisher","first-page":"102931","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-022-2212-5","article-title":"CARs: a new approach for the treatment of autoimmune diseases","volume":"66","author":"Sun","year":"2023","journal-title":"Sci China Life Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.10.4318","article-title":"Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells","volume":"91","author":"Moritz","year":"1994","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4161\/onci.19855","article-title":"OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells","volume":"1","author":"Hombach","year":"2012","journal-title":"Oncoimmunology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.11.063","article-title":"CAR T cells releasing IL-18 convert to T-bet(high) foxO1(low) effectors that exhibit augmented activity against advanced solid tumors","volume":"21","author":"Chmielewski","year":"2017","journal-title":"Cell Rep"},{"key":"B50","doi-asserted-by":"publisher","first-page":"100080","DOI":"10.1016\/j.xcrm.2020.100003","article-title":"Therapeutic targeting of follicular T cells with chimeric antigen receptor-expressing natural killer cells","volume":"1","author":"Reighard","year":"2020","journal-title":"Cell Rep Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.581433","article-title":"Antigen specificity enhances disease control by tregs in vitiligo","volume":"11","author":"Mukhatayev","year":"2020","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002328","article-title":"Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells","volume":"9","author":"Bai","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"104236","DOI":"10.1016\/j.cellimm.2020.104236","article-title":"Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity","volume":"358","author":"Janssens","year":"2020","journal-title":"Cell Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00733-w","article-title":"Regulatory T cells in autoimmune kidney diseases and transplantation","volume":"19","author":"Mikami","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2012495117","article-title":"A biomimetic five-module chimeric antigen receptor ((5M)CAR) designed to target and eliminate antigen-specific T cells","volume":"117","author":"Kobayashi","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.04.006","article-title":"La\/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease","volume":"192","author":"Meng","year":"2018","journal-title":"Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212757","article-title":"Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease","volume":"14","author":"Vakrakou","year":"2023","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04580709","article-title":"Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases","volume":"5","author":"Vincenti","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Transl Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0930-5","article-title":"Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma with renal impairment","volume":"55","author":"Li","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-021-2373-7","article-title":"Anti-BCMA CAR-T cell therapy in relapsed or refractory multiple myeloma patients with impaired renal function","volume":"41","author":"He","year":"2021","journal-title":"Curr Med Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"Sidana","year":"2024","journal-title":"Haematologica"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003783","article-title":"First report of CART treatment in AL amyloidosis and relapsed\/refractory multiple myeloma","volume":"9","author":"Oliver-Caldes","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"B70","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40364-023-00532-2","article-title":"First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma","volume":"11","author":"Korell","year":"2023","journal-title":"biomark Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0637","article-title":"Feasibility of a novel academic BCMA-CART (HBI0101) for the treatment of relapsed and refractory AL amyloidosis","volume":"28","author":"Kfir-Erenfeld","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2017.03.077","article-title":"Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis","volume":"19","author":"Rosenzweig","year":"2017","journal-title":"Cytotherapy"},{"key":"B73","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-022-00266-1","article-title":"Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis","volume":"11","author":"Hunter","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.08.017","article-title":"Acute kidney injury after the CAR-T therapy tisagenlecleucel","volume":"77","author":"Lee","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B76","doi-asserted-by":"publisher","first-page":"sfae027","DOI":"10.1093\/ckj\/sfae027","article-title":"Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological Malignancies","volume":"17","author":"Leon-Roman","year":"2024","journal-title":"Clin Kidney J"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-051116-052225","article-title":"Understanding human autoimmunity and autoinflammation through transcriptomics","volume":"35","author":"Banchereau","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0480-7","article-title":"New insights into the role of antinuclear antibodies in systemic lupus erythematosus","volume":"16","author":"Pisetsky","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.003","article-title":"A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients","volume":"14","author":"Yaniv","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses","volume":"125","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"100645","DOI":"10.1016\/j.blre.2019.100645","article-title":"Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential","volume":"41","author":"Haddadi","year":"2020","journal-title":"Blood Rev"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/art.40737","article-title":"Adoptive treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall\u2019Era","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised","volume":"79","author":"He","year":"2020","journal-title":"double-blind placebo-controlled trial Ann Rheum Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04160413","article-title":"Glomerular diseases: membranous nephropathy\u2013a modern view","volume":"9","author":"Ponticelli","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B85","first-page":"64","article-title":"Secondary membranous glomerulonephritis","author":"Glassock","year":"1992","journal-title":"Nephrol Dial Transplant"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104936","article-title":"The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis","volume":"9","author":"Du","year":"2014","journal-title":"PloS One"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005010028","article-title":"Management of membranous nephropathy: when and what for treatment","volume":"16","author":"Cattran","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.09.048","article-title":"Membranous nephropathy: integrating basic science into improved clinical management","volume":"91","author":"Cattran","year":"2017","journal-title":"Kidney Int"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.02.009","article-title":"Rituximab resistance","volume":"24","author":"Rezvani","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.822508","article-title":"Strategies towards antigen-specific treatments for membranous nephropathy","volume":"13","author":"Kollner","year":"2022","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.04.031","article-title":"ANCA-associated vasculitis: core curriculum 2020","volume":"75","author":"Geetha","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.103","article-title":"Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease","volume":"10","author":"Jennette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00256","article-title":"Neutrophil extracellular traps in ANCA-associated vasculitis","volume":"7","author":"Soderberg","year":"2016","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-014-0431-y","article-title":"B cell-mediated pathogenesis of ANCA-mediated vasculitis","volume":"36","author":"Jennette","year":"2014","journal-title":"Semin Immunopathol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez605","article-title":"B-cell treatment in ANCA-associated vasculitis","volume":"59","author":"Karras","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908576116","article-title":"Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus","volume":"116","author":"Mistry","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B103","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury","volume":"83","author":"Lodka","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/art.37959","article-title":"Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population","volume":"65","author":"Free","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/art.22692","article-title":"Functional defect of circulating regulatory CD4+ T cells in patients with Wegener\u2019s granulomatosis in remission","volume":"56","author":"Abdulahad","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B106","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molimm.2019.11.010","article-title":"Reduced activated regulatory T cells and imbalance of Th17\/activated Treg cells marks renal involvement in ANCA-associated vasculitis","volume":"118","author":"Wang","year":"2020","journal-title":"Mol Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02170","article-title":"Increased miR-142-3p expression might explain reduced regulatory T cell function in granulomatosis with polyangiitis","volume":"10","author":"Dekkema","year":"2019","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1080\/10428190601126602","article-title":"Renal failure in multiple myeloma: incidence, correlations, and prognostic significance","volume":"48","author":"Eleutherakis-Papaiakovou","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1159\/000442511","article-title":"Current trends of renal impairment in multiple myeloma","volume":"1","author":"Yadav","year":"2016","journal-title":"Kidney Dis (Basel)"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1210003","article-title":"Managing renal complications in multiple myeloma","volume":"9","author":"Fotiou","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2017.09.007","article-title":"The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed\/refractory multiple myeloma in the era of novel therapies","volume":"9","author":"Hari","year":"2018","journal-title":"J Geriatr Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23416","article-title":"Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients","volume":"34","author":"Chen","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.20","article-title":"Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma","volume":"5","author":"Gonsalves","year":"2015","journal-title":"Blood Cancer J"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.11.010","article-title":"Management of acute kidney injury in symptomatic multiple myeloma","volume":"99","author":"Bridoux","year":"2021","journal-title":"Kidney Int"},{"key":"B116","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41467-024-44873-4","article-title":"Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth","volume":"15","author":"Sun","year":"2024","journal-title":"Nat Commun"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12191","article-title":"Light chain amyloidosis 2012: a new era","volume":"160","author":"Gatt","year":"2013","journal-title":"Br J Haematol"},{"key":"B118","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light chain (AL) amyloidosis: the journey to diagnosis","volume":"11","author":"McCausland","year":"2018","journal-title":"Patient"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1177\/0300060518814337","article-title":"Multiorgan involvement by amyloid light chain amyloidosis","volume":"47","author":"Li","year":"2019","journal-title":"J Int Med Res"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.04.029","article-title":"Dysproteinemia and the kidney: core curriculum 2019","volume":"74","author":"Hogan","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B123","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000495455","article-title":"Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis","volume":"141","author":"Vaxman","year":"2019","journal-title":"Acta Haematologica"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000147","article-title":"Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone","volume":"3","author":"Kastritis","year":"2019","journal-title":"Blood Adv"},{"key":"B126","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"New Engl J Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26569","article-title":"Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment","volume":"97","author":"Gertz","year":"2022","journal-title":"Am J Hematol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000305","article-title":"AL amyloidosis: untangling new therapies","volume":"2021","author":"Bal","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280169","article-title":"Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma","volume":"107","author":"Harush","year":"2022","journal-title":"Haematologica"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2021.0709","article-title":"Regulatory T cells in COVID-19","volume":"12","author":"Wang","year":"2021","journal-title":"Aging Dis"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1395","article-title":"Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors","volume":"26","author":"Zakrzewski","year":"2008","journal-title":"Nat Biotechnol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0042-2","article-title":"CAR T cells for infection, autoimmunity and allotransplantation","volume":"18","author":"Maldini","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"104220","DOI":"10.1016\/j.cellimm.2020.104220","article-title":"Building a CAR-Treg: Going from the basic to the luxury model","volume":"358","author":"Rosado-Sanchez","year":"2020","journal-title":"Cell Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00968-8","article-title":"Chimeric receptors broaden the therapeutic landscape for autoimmune disease","volume":"19","author":"Finkel","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.67","article-title":"Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1","volume":"21","author":"Heinrich","year":"2013","journal-title":"Mol Ther"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41467-023-44648-3","article-title":"Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.7182","article-title":"Features and factors associated with myeloid neoplasms after chimeric antigen receptor T-cell therapy","volume":"10","author":"Gurney","year":"2024","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1408718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T04:39:17Z","timestamp":1724128757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1408718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":140,"alternative-id":["10.3389\/fimmu.2024.1408718"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1408718","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"article-number":"1408718"}}